Comparisons

Semaglutide vs Liraglutide: Which Performs Better?

GLP-1 Companion · 8 min read

Semaglutide and liraglutide are the two best-known GLP-1 receptor agonists developed by Novo Nordisk. Liraglutide came first, approved as Victoza for type 2 diabetes in 2010 and as Saxenda for obesity in 2014. Semaglutide followed as Ozempic for T2D in 2017 and Wegovy for obesity in 2021. Both drugs work through the same receptor but have meaningfully different clinical profiles. This article compares them across efficacy, safety, dosing, and real-world considerations including the 2025 availability of generic liraglutide.

How They Work: Same Receptor, Different Molecules

Both semaglutide and liraglutide are synthetic analogues of the endogenous GLP-1 hormone, modified to resist enzymatic degradation and extend half-life. Liraglutide has 97% amino acid sequence homology to native GLP-1 and is conjugated to a C-16 fatty acid chain that promotes self-association and albumin binding, resulting in a half-life of approximately 13 hours — sufficient for once-daily dosing. Semaglutide has a different fatty acid attachment and two amino acid substitutions in the peptide backbone that dramatically increase resistance to dipeptidyl peptidase-4 (DPP-4) degradation, producing a half-life of approximately 7 days and enabling once-weekly dosing.

SUSTAIN-10: The Head-to-Head Diabetes Trial

The SUSTAIN-10 trial (published 2019) was a randomized, open-label, multicenter study that directly compared semaglutide 1.0 mg once weekly versus liraglutide 1.2 mg once daily in 577 patients with type 2 diabetes over 30 weeks.

• HbA1c reduction: Semaglutide 1.0 mg reduced HbA1c by 1.7% vs liraglutide 1.2 mg which reduced it by 1.0% (statistically significant superiority for semaglutide)
• Body weight reduction: Semaglutide reduced body weight by 5.8 kg vs liraglutide 1.9 kg (statistically significant superiority for semaglutide)
• Achievement of HbA1c <7%: 79% on semaglutide vs 67% on liraglutide
• Gastrointestinal side effects: More common with semaglutide (42%) vs liraglutide (33%) during the trial period
• Discontinuation due to GI events: ~5% on semaglutide vs ~3% on liraglutide

SUSTAIN-10 is the definitive head-to-head comparison for the diabetes indication. Semaglutide 1.0 mg clearly outperformed liraglutide 1.2 mg on both primary efficacy endpoints. The study used liraglutide at 1.2 mg rather than the maximum 1.8 mg dose, which may slightly underestimate liraglutide's potential, but the differences were substantial enough to remain clinically meaningful.

Weight Loss for Obesity: SCALE vs STEP Trials

For weight management, the relevant comparison is between liraglutide 3.0 mg (SCALE trials) and semaglutide 2.4 mg (STEP trials). These are not head-to-head trials, so comparison must be made with appropriate caution about population differences.

• SCALE Obesity and Prediabetes (liraglutide 3.0 mg, 56 weeks): Average weight loss 8.4% of body weight
• SCALE Diabetes (liraglutide 3.0 mg, 56 weeks): Average weight loss 6.0% of body weight
• STEP 1 (semaglutide 2.4 mg, 68 weeks, no diabetes): Average weight loss 14.9% of body weight
• STEP 2 (semaglutide 2.4 mg, 68 weeks, with T2D): Average weight loss 9.6% of body weight
• Percentage achieving ≥5% weight loss: ~63% (liraglutide) vs ~86% (semaglutide)
• Percentage achieving ≥10% weight loss: ~33% (liraglutide) vs ~70% (semaglutide)
• Percentage achieving ≥15% weight loss: ~16% (liraglutide) vs ~51% (semaglutide)

The magnitude of difference in obesity trials is substantial. For a person starting at 250 pounds, the SCALE vs STEP data suggests a difference of approximately 21 pounds (SCALE) versus 37 pounds (STEP 1) of expected weight loss on average. In practice, individual responses vary considerably, but the population-level advantage for semaglutide is clear.

Cardiovascular Outcomes Evidence

Both semaglutide and liraglutide have demonstrated cardiovascular benefits in major outcomes trials, but the evidence differs in scope and patient population.

• LEADER trial (liraglutide 1.8 mg, T2D with high CV risk): 13% reduction in major adverse cardiovascular events (MACE) vs placebo over ~3.5 years; FDA approved liraglutide for CV risk reduction in T2D in 2017
• SUSTAIN-6 (semaglutide 0.5 mg and 1.0 mg, T2D): 26% reduction in MACE vs placebo; FDA approved Ozempic for CV risk reduction in T2D in 2020
• SELECT trial (semaglutide 2.4 mg, obesity without T2D): 20% reduction in MACE vs placebo in patients with established CVD — the first GLP-1 CV outcomes trial in non-diabetic obesity
• No equivalent SELECT-style trial for liraglutide 3.0 mg in obesity without T2D

The SELECT trial is a particularly important differentiator. Semaglutide now has demonstrated CV benefit across three distinct patient populations (T2D, and obesity without T2D). Liraglutide's CV evidence, while strong, is limited to patients with type 2 diabetes. For patients with obesity and cardiovascular disease who do not have T2D, semaglutide's SELECT data provides a clinically meaningful additional reason to prefer it over liraglutide.

Dosing and Convenience

• Liraglutide (Victoza, Saxenda): Once-daily subcutaneous injection; Saxenda titrated over 5 weeks to 3.0 mg; Victoza titrated to 1.2 or 1.8 mg over 2-3 weeks
• Semaglutide (Ozempic, Wegovy): Once-weekly subcutaneous injection; Ozempic titrated over 8-12 weeks; Wegovy titrated over 16 weeks to 2.4 mg
• Annual injection burden: Approximately 365 injections/year for liraglutide vs approximately 52/year for semaglutide
• Real-world adherence: Studies consistently show better medication persistence with once-weekly vs once-daily injectable GLP-1 therapies

Side Effect Profiles

Both drugs produce GI-dominant side effects due to shared GLP-1 receptor activity, particularly during dose escalation.

• Nausea rates: ~39% (liraglutide 3.0 mg, SCALE) vs ~44% (semaglutide 2.4 mg, STEP 1)
• Diarrhea rates: ~21% (liraglutide) vs ~30% (semaglutide)
• Vomiting rates: ~15% (liraglutide) vs ~24% (semaglutide)
• Discontinuation due to GI effects: ~9% (liraglutide) vs ~7% (semaglutide, STEP 1)
• Both carry identical black-box warnings for thyroid C-cell tumor risk
• Heart rate elevation: Both increase resting heart rate by approximately 2-4 bpm; more pronounced with liraglutide in some analyses

Generic Liraglutide: How It Changes the Calculus

The August 2025 FDA approval of Teva's generic liraglutide 3.0 mg is the most significant recent development affecting the semaglutide vs liraglutide comparison. While semaglutide remains clinically superior in both head-to-head and comparative trial data, the cost difference has shifted dramatically.

• Generic liraglutide 3.0 mg: approximately $300 to $500 per month as of early 2026
• Brand Wegovy (semaglutide 2.4 mg): approximately $1,350 per month without insurance or savings card
• For uninsured patients without access to manufacturer savings programs, generic liraglutide offers a 60-70% cost reduction vs brand semaglutide
• For patients with Medicaid: several state formularies cover liraglutide but not semaglutide for obesity

When Liraglutide Is Still the Right Choice

• Cost-constrained patients who cannot access semaglutide through insurance or savings programs
• Medicaid patients in states where liraglutide is on formulary but semaglutide is not
• Patients who achieved adequate weight loss (≥5% body weight) and metabolic improvement on liraglutide and want to continue cost-effectively with generics
• Adolescents 12 to 17 (Saxenda has this approval; coverage access may vary from Wegovy for this age group)
• Patients who particularly prefer daily injections or have had tolerability issues with once-weekly semaglutide

The SUSTAIN-10 trial makes clear that semaglutide outperforms liraglutide in head-to-head comparison. The SCALE vs STEP data confirms this extends to weight management. The question is not which drug is better clinically, but which is accessible and affordable for a specific patient.

The Bottom Line

Semaglutide is the superior GLP-1 agent when comparing clinical efficacy: it reduces HbA1c more, produces greater weight loss at all comparison points, requires only weekly rather than daily injections, and carries stronger cardiovascular evidence across a broader range of patient populations. Liraglutide remains clinically appropriate — and now more affordable than ever with generic availability — for patients with access, cost, or formulary constraints. The right choice for any individual patient depends on their complete clinical and financial picture.

Sources

• Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM.
• Pi-Sunyer et al. (2015). Liraglutide 3.0 mg in Weight Management. NEJM.